Point-of-care antigen test earns FDA emergency use authorization

The Food and Drug Administration Monday authorized the emergency use of the BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2.
The test is the second antigen diagnostic to earn an emergency use authorization from FDA and can be used in patient care settings approved for CLIA high or moderate complexity or waived testing.
However, the test’s emergency use is limited to authorized laboratories using the BD Veritor Plus Analyzer Instrument.
Related News Articles
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…